This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. June 3, ...
Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...
A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...
You may get medicines before infliximab to reduce the chance you will have side effects from the infusion. Some people, depending on why they are using infliximab, may be able to change to giving ...
LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...
Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...
The FDA has approved Celltrion's biosimilar version of Johnson & Johnson's Remicade, cracking open a big market for one of the world's top blockbusters. This is the second biosimilar approved by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback